Rating History for Silverback Therapeutics (SBTX) by Goldman Sachs

More Stocks Rated by Goldman Sachs | Latest Ratings for SBTX
Date Analyst Type Rating
(Past)		 PT
(Past)		 Start $
(End $)		 % Chg. Details
4/4/2022 Paul Choi Downgrade Neutral
(Buy)		 3.50
(25.00)		 3.51
(5.87)		 67.24% Details